How Ideas2IT Built the Clinical Data Management Platform That Moves a Global Pharmaceutical Company's Trials from Audit Risk to Regulatory Confidence
A global pharmaceutical company was running clinical trial QA on manual workflows that let data inconsistencies reach audit. Ideas2IT built a modular AI platform to detect, recover, and standardize trial data in real time, moving compliance upstream of the submission process.
Client
Global pharma leader
Industry
Pharma & Life Sciences
Service
Data Engineering
Compliance
FDA · EMA · CDISC SDTM
Location
USA
01 Challenge
Clinical data across EDCs, CRFs, and patient registries produced inconsistencies that spreadsheet QA couldn't catch at scale. Missing values, input errors, and protocol deviations surfaced at audit, when the cost and timeline impact were already locked in and FDA and EMA submissions were already at risk.
02 Solution
Ideas2IT built the detection engine first: AI models cross-referencing clinical data across systems against historical patterns and protocol benchmarks to route mismatches before they compounded. A missing data recovery module and anomaly detection layer completed the dataset and flagged deviations. All corrected outputs were standardized to CDISC SDTM as a pipeline default.
03 Outcome
Data review cycles shortened. Submission readiness improved with CDISC SDTM-aligned outputs traceable to correction events. Analyst time shifted from manual QA to exception review, and the clinical team gained regulatory confidence ahead of the submission window.
Phase 01
Making data conflicts visible at ingestion.
Inconsistency detection and cross-system validation: catching data conflicts before they compound
Clinical trial data doesn't live in one system. EDCs, CRFs, and patient registries each produce records in different formats, updated on different schedules, by different site teams. Inconsistencies accumulate across them without any single system surfacing the conflict.
Ideas2IT built the detection engine as the first architectural layer: AI models cross-referencing data across all source systems against historical patterns and protocol benchmarks, identifying mismatches and routing them for review before they reached downstream QA.
The engine required no unified data model upfront, operating directly against each source system's native format.
Phase 02
Filling gaps with traceable inference before the QA cycle opens
Missing data recovery and anomaly detection: completing the dataset before audit review begins
The second failure mode was invisible: missing values from input errors, site variability, and subject dropout, and protocol deviations in patient cohorts that rule-based monitoring never flagged.
Ideas2IT built a missing data recovery module using statistical and contextual inference models that identified gaps, suggested imputation paths, and flagged every predicted value with provenance so analysts could review rather than guess.
On top of that, an anomaly detection layer scanned for outliers, unexpected cohort trends, and protocol deviations across the full trial timeline. Quality assurance shifted from a final-stage audit gate to a continuous upstream process.
Phase 03
Embedding compliance in the output, not formatting it after the fact
CDISC SDTM standardization and audit trail: regulatory-ready output as a pipeline default
The compliance gap most teams face is structural: CDISC SDTM standardization is treated as a formatting task applied after data is clean, which means errors discovered during that step require another remediation cycle.
Ideas2IT embedded SDTM standardization directly in the pipeline output layer, so every corrected record exited the platform in submission-ready format. The audit trail service captured every correction event with full traceability across the data lifecycle, meeting FDA inspection requirements.
The full platform deployed as containerized, API-accessible services on AWS, built to scale across trial phases and add new data sources without architectural rework.
The Outcome
Data integrity built upstream, submission confidence delivered at scale
The platform moved the compliance work where it belongs: upstream, in the pipeline, before a submission window opens. Embedding CDISC SDTM standardization as an output default and building the audit trail as a first-class pipeline component meant that every corrected record was submission-ready by the time it left the system. For a pharmaceutical company operating under FDA and EMA scrutiny, that architectural decision is the difference between a remediation cycle and a submission.